The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators
- 30 November 2003
- journal article
- Published by Elsevier BV in Surgery
- Vol. 134 (5), 827-834
- https://doi.org/10.1016/s0039-6060(03)00292-7
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Immunogene therapy with interleukin-2—secreting fibroblasts for intracerebrally metastasizing breast cancer in miceJournal of Neurosurgery, 2001
- High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II studyBone Marrow Transplantation, 2000
- Review Article The immunology and immunotherapy of breast cancer: an updateInternational Journal of Immunopharmacology, 1999
- Combination Therapy with Interleukin-2 and Wild-Type p53 Expressed by Adenoviral Vectors Potentiates Tumor Regression in a Murine Model of Breast CancerHuman Gene Therapy, 1998
- Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical studyInternational Journal of Cancer, 1997
- Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2)Radiation Oncology Investigations, 1997
- Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinomas–correlation with tumour differentiationThe Journal of Pathology, 1990
- Same peculiar subset of HML1 + lymphocytes present within normal intestinal epithelium is associated with tumoral epithelium of gastrointestinal carcinomas.Gut, 1988
- Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breastThe Journal of Pathology, 1987
- Mononuclear cells infiltrating human mammary carcinomas: Immunohistochemical analysis with monoclonal antibodiesInternational Journal of Cancer, 1985